Dgs Capital Management, LLC Biogen Inc. Transaction History

Dgs Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 30, 2024	BUY	$222.59 - $267.94 $11,352 - $13,664	51 Added 4.2%	1,265 $327,000
Q3 2023 Jan 30, 2024	SELL	$253.3 - $285.89 $43,061 - $48,601	-170 Reduced 12.28%	1,214 $312,000
Q2 2023 Jan 30, 2024	BUY	$275.25 - $318.06 $13,212 - $15,266	48 Added 3.59%	1,384 $394,000
Q1 2023 Jun 16, 2023	SELL	$256.56 - $292.34 $90,309 - $102,903	-352 Reduced 20.85%	1,336 $371,000
Q4 2022 Feb 21, 2023	BUY	$252.44 - $306.72 $179,484 - $218,077	711 Added 72.77%	1,688 $467,000
Q3 2022 Feb 21, 2023	BUY	$194.69 - $268.46 $190,212 - $262,285	977 New	977 $260,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Dgs Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Dgs Capital Management, LLC with notifications on news.